Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside
Top Cited Papers
Open Access
- 1 January 2024
- journal article
- review article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 14 (4) , 1720-1743
Abstract
Terbium features four clinically interesting radionuclides for application in nuclear medicine: terbium-149, terbium-152, terbium-155, and terbium-161. Their identical chemical properties enable the synthesis of radiopharmaceuticals with the same pharmacokinetic character, while their distinctive decay characteristics make them valuable for both imaging and therapeutic applications. In particular, terbium-152 and terbium-155 are useful candidates for positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging, respectively; whereas terbium-149 and terbium-161 find application in α- and β--/Auger electron therapy, respectively. This unique characteristic makes the terbium family ideal for the “matched-pair” principle of theranostics. In this review, the advantages and challenges of terbium-based radiopharmaceuticals are discussed, covering the entire chain from radionuclide production to bedside administration. It elaborates on the fundamental properties of terbium, the production routes of the four interesting radionuclides and gives an overview of the available bifunctional chelators. Finally, we discuss the preclinical and clinical studies as well as the prospects of this promising development in nuclear medicine.Keywords
This publication has 86 references indexed in Scilit:
- New pharmaceuticals approved by FDA in 2020: Small‐molecule drugs derived from amino acids and related compoundsChirality, 2021
- Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicityEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Synthesis and Evaluation of a Macrocyclic Actinium‐225 Chelator, Quality Control and In Vivo Evaluation of 225Ac‐crown‐αMSH PeptideChemistry – A European Journal, 2020
- Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer modelEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugateEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximabEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004
- Separation of carrier free152, 153Dy and151–153Tb from16O7+ irradiated CeO2 by liquid-liquid extractionJournal of Radioanalytical and Nuclear Chemistry, 1999
- (α,3pxn) or (α,αpxn) reactions on natural dysprosiumJournal of Radioanalytical and Nuclear Chemistry, 1997
- Evaluation in vitro and in rats of161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 1995